Wegovy (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
If you experience intense nausea specifically during menstruation, your healthcare provider may adjust your meal timing, suggest anti-nausea strategies, or recommend dividing your weekly dose differentlythough the total dose stays the same
Peptide therapy in Carson City offers a scientifically-backed solution to help you achieve your weight loss goals
Tirzepatide has a boxed warning for the risk of thyroid C-cell tumors
Behavior is modified to obtain specific foods, and cognitive modulation enhances the adaptability of these behaviors
[1] Clinical investigations have yielded highly promising outcomes